Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients.
Trace element
adenocarcinoma
driver mutation
lung cancer
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
21
12
2019
Statut:
ppublish
Résumé
This study aimed to observe the association between trace element concentrations in lung tissue from lung adenocarcinoma cancer (LADC) patients and mutations in the epidermal growth factor receptor ( LADC patients who had undergone lung resection were included in this study. Furthermore, twenty patients without lung cancer were included in this study as the control group. Samples were separately collected from both tumor and peritumor tissues. The mutational status was assessed for EGFR mutations, ALK rearrangements and KRAS mutations. Based on these analyses, patients were grouped into three groups: EGFR mutation, KRAS mutation and wild-type groups. The concentrations of various trace elements in the lung tissues were measured by a particle-induced X-ray emission (PIXE) system, and the results were analyzed for statistical significance. A total of 110 LADC patients were included in this study. The median age was 70 years, and 60% of the participants were female. Moreover, 18% and 20% of patients were EGFR- and KRAS-positive, respectively. Thirty-two trace elements were measured, and 18 trace elements were detectable. The concentrations of Fe, Co, Ni, Cu, Zn and Br were significantly higher in the KRAS mutation and wild-type groups than in the control group regardless of whether the samples were from tumor or peritumor tissues. For these 6 trace elements, the concentrations were significantly higher in smokers than in non-smokers. Considering the effect of smoking, differences in the trace element concentrations between each mutational group remained. Trace elements in the lung may play a role in development of LADC in both smokers and never-smokers. However, prospective studies with larger sample sizes are needed to support this hypothesis.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to observe the association between trace element concentrations in lung tissue from lung adenocarcinoma cancer (LADC) patients and mutations in the epidermal growth factor receptor (
METHODS
METHODS
LADC patients who had undergone lung resection were included in this study. Furthermore, twenty patients without lung cancer were included in this study as the control group. Samples were separately collected from both tumor and peritumor tissues. The mutational status was assessed for EGFR mutations, ALK rearrangements and KRAS mutations. Based on these analyses, patients were grouped into three groups: EGFR mutation, KRAS mutation and wild-type groups. The concentrations of various trace elements in the lung tissues were measured by a particle-induced X-ray emission (PIXE) system, and the results were analyzed for statistical significance.
RESULTS
RESULTS
A total of 110 LADC patients were included in this study. The median age was 70 years, and 60% of the participants were female. Moreover, 18% and 20% of patients were EGFR- and KRAS-positive, respectively. Thirty-two trace elements were measured, and 18 trace elements were detectable. The concentrations of Fe, Co, Ni, Cu, Zn and Br were significantly higher in the KRAS mutation and wild-type groups than in the control group regardless of whether the samples were from tumor or peritumor tissues. For these 6 trace elements, the concentrations were significantly higher in smokers than in non-smokers. Considering the effect of smoking, differences in the trace element concentrations between each mutational group remained.
CONCLUSIONS
CONCLUSIONS
Trace elements in the lung may play a role in development of LADC in both smokers and never-smokers. However, prospective studies with larger sample sizes are needed to support this hypothesis.
Identifiants
pubmed: 31857947
doi: 10.21037/tlcr.2019.08.18
pii: tlcr-08-S3-S224
pmc: PMC6894994
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S224-S234Informations de copyright
2019 Translational Lung Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Ann Oncol. 2013 Sep;24(9):2371-6
pubmed: 23723294
Eur Respir J. 2014 Oct;44(4):994-1001
pubmed: 25034571
Cancer Causes Control. 2012 Jun;23(6):807-18
pubmed: 22527160
J Arthroplasty. 1995 Feb;10(1):75-82
pubmed: 7730834
Cancer Sci. 2009 Jan;100(1):9-16
pubmed: 19018762
Clin Chim Acta. 2016 Jan 15;452:142-8
pubmed: 26585752
PLoS One. 2014 Jun 18;9(6):e99790
pubmed: 24941118
Eur Respir J. 2016 Nov;48(5):1462-1470
pubmed: 27799390
Lung Cancer. 2010 Sep;69(3):272-8
pubmed: 20022659
Clin Epidemiol. 2011;3:139-48
pubmed: 21607015
Environ Res. 2018 Oct;166:269-275
pubmed: 29908458
Nat Biotechnol. 1999 Aug;17(8):804-7
pubmed: 10429248
Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5
pubmed: 19349489
Carcinogenesis. 1995 Feb;16(2):335-42
pubmed: 7859366
J Cancer Res Ther. 2018 Dec;14(Supplement):S1152-S1157
pubmed: 30539862
J Thorac Oncol. 2007 Jan;2(1):22-8
pubmed: 17410005
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1154-L1163
pubmed: 28912379
Part Fibre Toxicol. 2018 Jul 17;15(1):32
pubmed: 30016969
Crit Rev Oncol Hematol. 2002 Apr;42(1):57-64
pubmed: 11923068
Toxicol Appl Pharmacol. 1997 Mar;143(1):152-66
pubmed: 9073603
Arch Pathol Lab Med. 2018 Mar;142(3):321-346
pubmed: 29355391
Ann Occup Hyg. 1982;26(1-4):417-22
pubmed: 6295245
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Curr Med Chem. 2013 Feb 1;20(6):789-93
pubmed: 23244523
Acta Biomed. 2008;79 Suppl 1:52-63
pubmed: 18924310
IUBMB Life. 2005 Dec;57(12):805-9
pubmed: 16393783
Biol Trace Elem Res. 2019 Apr;188(2):295-315
pubmed: 29974385
J Trace Elem Med Biol. 2018 Jan;45:78-84
pubmed: 29173487
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Environ Mol Mutagen. 2000;36(2):151-60
pubmed: 11013414
Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):988-92
pubmed: 22523180
Mutat Res. 2003 Dec 10;533(1-2):67-97
pubmed: 14643413
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Onco Targets Ther. 2016 Feb 22;9:833-43
pubmed: 26955281
Int J Chron Obstruct Pulmon Dis. 2018 May 31;13:1803-1808
pubmed: 29910610
Clin Cancer Res. 2009 Sep 15;15(18):5646-61
pubmed: 19755392
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
J Trace Elem Med Biol. 2018 Jan;45:70-77
pubmed: 29173486
Nat Rev Cancer. 2007 Oct;7(10):778-90
pubmed: 17882278